After finishing at $47.70 in the prior trading day, Sanofi ADR (NASDAQ: SNY) closed at $47.96, up 0.55%. In other words, the price has increased by $+0.26 from its previous closing price. On the day, 1362268 shares were traded.
Ratios:
Our goal is to gain a better understanding of SNY by taking a closer look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 12.48 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 13.00. For the most recent quarter (mrq), Quick Ratio is recorded 0.87 and its Current Ratio is at 1.27. In the meantime, Its Debt-to-Equity ratio is 0.25 whereas as Long-Term Debt/Eq ratio is at 0.22.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Morgan Stanley on January 23, 2024, initiated with a Equal-Weight rating and assigned the stock a target price of $55.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, SNY now has a Market Capitalization of 119.26B and an Enterprise Value of 129.45B. As of this moment, Sanofi’s Price-to-Earnings (P/E) ratio for their current fiscal year is 20.65, and their Forward P/E ratio for the next fiscal year is 10.18. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 2.29. For the stock, the TTM Price-to-Sale (P/S) ratio is 2.58 while its Price-to-Book (P/B) ratio in mrq is 1.47. Its current Enterprise Value per Revenue stands at 2.79 whereas that against EBITDA is 10.27.
Stock Price History:
Over the past 52 weeks, SNY has reached a high of $57.82, while it has fallen to a 52-week low of $42.63. The 50-Day Moving Average of the stock is 48.04, while the 200-Day Moving Average is calculated to be 50.48.
Shares Statistics:
The stock has traded on average 1.85M shares per day over the past 3-months and 2.11M shares per day over the last 10 days, according to various share statistics. A total of 2.50B shares are outstanding, with a floating share count of 2.50B. Insiders hold about 0.02% of the company’s shares, while institutions hold 9.92% stake in the company. Shares short for SNY as of Mar 15, 2024 were 4.59M with a Short Ratio of 2.48, compared to 4.06M on Feb 15, 2024.
Dividends & Splits
In the trailing 12 months, SNY’s forward annual dividend rate was 3.76, compared to 1.90 this year. Against a Trailing Annual Dividend Yield of 7.88%, it implies a Forward Annual Dividend Yield of 4.27%. The stock’s 5-year Average Dividend Yield is 3.72. The current Payout Ratio is 87.37% for SNY, which recently paid a dividend on Jun 23, 2023 with an ex-dividend date of May 09, 2024. Stock splits for the company last occurred on Sep 30, 2013 when the company split stock in a 5:1 ratio.
Earnings Estimates
Its stock is currently analyzed by 1 different market analysts. On average, analysts expect EPS of $1.92 for the current quarter, with a high estimate of $1.92 and a low estimate of $1.92, while EPS last year was $1.16. The consensus estimate for the next quarter is $1.8, with high estimates of $1.8 and low estimates of $1.8.
Analysts are recommending an EPS of between $4.29 and $4.16 for the fiscal current year, implying an average EPS of $4.22. EPS for the following year is $4.94, with 2 analysts recommending between $5.04 and $4.83.
Revenue Estimates
3 analysts predict $11.77B in revenue for the current quarter. It ranges from a high estimate of $12.09B to a low estimate of $11.2B. As of the current estimate, Sanofi ADR’s year-ago sales were $11.33B, an estimated increase of 3.90% from the year-ago figure. For the next quarter, 3 analysts are estimating revenue of $11.93B, an increase of 6.20% over than the figure of $3.90% in the same quarter last year. There is a high estimate of $12.46B for the next quarter, whereas the lowest estimate is $11.32B.
A total of 15 analysts have provided revenue estimates for SNY’s current fiscal year. The highest revenue estimate was $53.91B, while the lowest revenue estimate was $47.84B, resulting in an average revenue estimate of $50.67B. In the same quarter a year ago, actual revenue was $46.57B, up 8.80% from the average estimate. Based on 14 analysts’ estimates, the company’s revenue will be $54.19B in the next fiscal year. The high estimate is $57.14B and the low estimate is $51.62B. The average revenue growth estimate for next year is up 6.90% from the average revenue estimate for this year.
